It’s Monday
– time to turn to the European Hematology Association’s “Learning Monday”.
Perhaps
the start of learning is finding out what you don’t know.
Apparently Ruxolitinib
is indicated in patients with symptomatic splenomegaly and/or constitutional
symptoms due to IM-2 and HR PMF. Bearing in mind I don’t know what Ruxolitinib IM-2
or HR PMF are, there’s the start of today’s CPD…
No comments:
Post a Comment